对于COVID-19的门诊患者进行血栓预防:系统性审查和元分析
Cho-Han Chiang1, Omer Ahmed2, Weitao Liu3
1Department of Medicine, Mount Auburn Hospital, Harvard Medical School, Cambridge, MA, USA.
Journal of thrombosis and thrombolysis
|April 26, 2024
概括
血栓预防疗法显著减少了COVID-19门诊患者的静脉血栓塞栓症的70%. 然而,它没有影响死亡率,心血管事件或住院率,同时增加了非重大出血风险.
科学领域:
- 医学研究 医学研究
- 临床试验 临床试验
- 公共卫生 公共卫生
背景情况:
- 感染COVID-19会增加发生血栓栓塞的风险.
- 血栓预防是住院患者的标准,但其在门诊患者的使用情况不太清楚.
- 这项研究针对非住院COVID-19患者的血栓预防治疗的安全性和有效性.
结论:
- 血栓预防疗法在COVID-19的门诊患者中有效预防VTE.
- 血栓预防的好处必须与增加的非重大出血风险进行权衡.
- 进一步的研究可能会澄清这种患者群体中血栓预防的最佳策略.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
687
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
687
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
522
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
522